-
Name:Belnacasan
Catalog No.:B0013
Structure:
Chemical Properties Cas No.:273404-37-8 Purity Limit: Synonyms: Molecular Weight:508.99 Formula:C24H33ClN4O6 Storage: Solubility:
Shipping Condition
Quality Control & MSDS
Description Belnacasan, also known as VX-765, is designed to inhibit Caspase, which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18. VX-765 has been shown to inhibit acute seizures in preclinical models. In addition, VX-765 has shown activity in preclinical models of chronic epilepsy. VX-765 had been dosed in over 100 patients in phase-I and phase-IIa clinical trials relating to other diseases, including a 28-day phase-IIa clinical trial in patients with psoriasis. It has completed the treatment phase of a phase-IIa clinical trial of VX-765 that enrolled approximately 75 patients with treatment-resistant epilepsy. The double-blind, randomized, placebo-controlled clinical trial was designed to evaluate the safety, tolerability and clinical activity of VX-765
References Related products
- Cobicistat
- Ispinesib
- Carfilzomib
- Talabostat
Tel: +86-411-39042497
sales@alphabiopham.com
Contact us now!
We'll offer you the best prices